Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy

Fig. 3

Synergistic effect of chidamide combined with enzalutamide in vitro. A, B Cell viability of MDA-MB-453 and CAL-148 cell lines treated with chidamide or enzalutamide. The IC50 values are shown in the left corner of each figure. C Heatmap showing the cell viability and CI value of chidamide and enzalutamide in MDA-MB-453 and CAL-148 cell lines at different drug concentrations

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us